Virax Biolabs
VRAX
4 hedge funds and large institutions have $195K invested in Virax Biolabs in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.
1,694% more capital invested
Capital invested by funds: $10.9K → $195K (+$184K)
0.29% more ownership
Funds ownership: 0% → 0.3% (+0.29%)
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$285K |
| 2 |
VF
Virtu Financial
New York
|
+$24.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.32K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.88K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $178K | +$285K | +4,880 | New |
|
|
VF
2
Virtu Financial
New York
| $16K | +$24.9K | +426 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $971 | +$1.52K | +26 | +2,600% |
|
4
Wells Fargo
San Francisco,
California
| $292 | – | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$5.32K | -65 | Closed |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$4.88K | -60 | Closed |
|
VRAX Hedge Fund Activity: Q4 2023 in Review
4 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q4 2023, worth a combined $195K — up 1,694% from $10.9K a quarter earlier.
Fund positioning in VRAX was balanced in Q4 2023: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $285K. The largest seller was Citadel Advisors, exiting entirely with an estimated $5.32K sold.
- 4 institutional investors held Virax Biolabs (VRAX) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $195K of Virax Biolabs stock for Q4 2023, up 1,694% quarter-over-quarter.
- 2 funds opened new Virax Biolabs positions in Q4 2023 and 2 closed out, a net change of 0 holders.
- The largest Virax Biolabs buyer in Q4 2023 was Armistice Capital, an estimated $285K added.
- The largest Virax Biolabs seller in Q4 2023 was Citadel Advisors, an estimated $5.32K sold.
Based on aggregated 13F filings for Q4 2023.